[go: up one dir, main page]

PE20060654A1 - CONJUGATES OF HUMAN GROWTH HORMONE AND BRANCHED POLYTILENGLYCOL WITH GLYCEROL AND PREPARATION PROCESS - Google Patents

CONJUGATES OF HUMAN GROWTH HORMONE AND BRANCHED POLYTILENGLYCOL WITH GLYCEROL AND PREPARATION PROCESS

Info

Publication number
PE20060654A1
PE20060654A1 PE2005000991A PE2005000991A PE20060654A1 PE 20060654 A1 PE20060654 A1 PE 20060654A1 PE 2005000991 A PE2005000991 A PE 2005000991A PE 2005000991 A PE2005000991 A PE 2005000991A PE 20060654 A1 PE20060654 A1 PE 20060654A1
Authority
PE
Peru
Prior art keywords
growth hormone
human growth
glycerol
branched
polytilenglycol
Prior art date
Application number
PE2005000991A
Other languages
Spanish (es)
Inventor
Rory Francis Finn
Ned Roger Siegel
Original Assignee
Pharmacia And Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia And Upjohn Company Llc filed Critical Pharmacia And Upjohn Company Llc
Publication of PE20060654A1 publication Critical patent/PE20060654A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A LA PEGILACION DE LA HORMONA DE CRECIMIENTO HUMANA (hGH) USANDO UN RESTO DE POLI(ETILENGLICOL) RAMIFICADO CON GLICEROL, OBTENIENDOSE UN CONJUGADO DE POLIETILENGLICOL-HORMONA DE CRECIMIENTO (PEG-hGH) DE FORMULA (I), EN LA QUE n ES UN NUMERO ENTERO COMPRENDIDO ENTRE 60 Y 75; m ENTRE 450 Y 460; Y R ES LA HORMONA DE CRECIMIENTO HUMANA, EN DONDE AL MENOS EL 80% DEL PEG ESTA CONJUGADO CON EL GRUPO ALFA-AMINO DE LA FENILALANINA N-TERMINAL DE LA SEC ID N°:1. ESTE CONJUGADO SE CARACTERIZA POR PRESENTAR PROPIEDADES QUIMICAS O FISICAS MEJORADAS, Y ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS DE CRECIMIENTO Y DESARROLLOREFERS TO THE PEGILATION OF HUMAN GROWTH HORMONE (hGH) USING A REST OF POLY (ETHYLENGLYCOL) BRANCHED WITH GLYCEROL, OBTAINING A CONJUGATE OF POLYETHYLENE GLYCOL-GROWTH HORMONE (PEG-hGH), IN THE FORMULA (n) IT IS A WHOLE NUMBER INCLUDED BETWEEN 60 AND 75; m BETWEEN 450 AND 460; AND R IS THE HUMAN GROWTH HORMONE, WHERE AT LEAST 80% OF THE PEG IS CONJUGATED WITH THE ALPHA-AMINO GROUP OF N-TERMINAL PHENYLALANINE OF SEQ ID N °: 1. THIS CONJUGATE IS CHARACTERIZED BY PRESENTING IMPROVED CHEMICAL OR PHYSICAL PROPERTIES, AND IS USEFUL IN THE TREATMENT OF GROWTH AND DEVELOPMENT DISORDERS

PE2005000991A 2004-08-31 2005-08-26 CONJUGATES OF HUMAN GROWTH HORMONE AND BRANCHED POLYTILENGLYCOL WITH GLYCEROL AND PREPARATION PROCESS PE20060654A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
PE20060654A1 true PE20060654A1 (en) 2006-08-12

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000991A PE20060654A1 (en) 2004-08-31 2005-08-26 CONJUGATES OF HUMAN GROWTH HORMONE AND BRANCHED POLYTILENGLYCOL WITH GLYCEROL AND PREPARATION PROCESS

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297889T3 (en) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR0008759B1 (en) 1999-01-14 2014-03-11 Bolder Biotechnology Inc Methods for the production of protein containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
MX2008014358A (en) * 2006-05-12 2008-11-24 Dong A Pharm Co Ltd Polyethylene glycol-interferon alpha conjugate.
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) * 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
ES2523043T3 (en) * 2008-07-23 2014-11-20 Hanmi Science Co., Ltd. A polypeptide complex comprising a non-peptidyl polymer having three functional ends
NZ591167A (en) 2008-07-31 2012-06-29 Pharmaessentia Corp Peptide-polymer conjugates
CN102245214B (en) * 2008-10-10 2014-10-29 波利艾克蒂瓦有限公司 Biodegradable polymer-bioactive moiety conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
ES2730800T3 (en) 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Extended recombinant polypeptides and compositions comprising the same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
EA037979B1 (en) * 2012-02-27 2021-06-18 Амуникс Оперейтинг Инк. Xten conjugate compositions and methods of making same
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
CN111801120A (en) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 Methods for providing pegylated protein compositions
EP3731873B1 (en) * 2017-12-29 2022-01-26 F. Hoffmann-La Roche AG Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
BR0008759B1 (en) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Methods for the production of protein containing free cysteine residues
CN1608079A (en) * 2001-11-20 2005-04-20 法玛西雅公司 Chemically-modified human growth hormone conjugates
KR100974843B1 (en) * 2002-09-09 2010-08-11 넥타르 테라퓨틱스 Water Soluble Polymer Alkanal
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
CA2509248A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
NZ541374A (en) * 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
BRPI0515118A (en) 2008-07-01
ZA200701802B (en) 2008-08-27
MX2007002441A (en) 2007-05-04
NO20071322L (en) 2007-05-29
NL1029828A1 (en) 2006-03-01
GT200500235A (en) 2006-03-21
TNSN07078A1 (en) 2008-06-02
CA2577999A1 (en) 2006-03-09
WO2006024953A3 (en) 2007-01-18
ECSP077281A (en) 2007-03-29
TW200621291A (en) 2006-07-01
MA28908B1 (en) 2007-10-01
AP2007003919A0 (en) 2007-02-28
AR050851A1 (en) 2006-11-29
EA200700380A1 (en) 2007-10-26
WO2006024953A2 (en) 2006-03-09
EP1789092A2 (en) 2007-05-30
IL181085A0 (en) 2007-07-04
JP2008511610A (en) 2008-04-17
CR8942A (en) 2007-08-16
KR20070042567A (en) 2007-04-23
CN101010105A (en) 2007-08-01
AU2005278903A1 (en) 2006-03-09
NL1029828C2 (en) 2006-10-20
UY29088A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
PE20060654A1 (en) CONJUGATES OF HUMAN GROWTH HORMONE AND BRANCHED POLYTILENGLYCOL WITH GLYCEROL AND PREPARATION PROCESS
AR047062A1 (en) CONJUGATED CARRIERS OF BETA IMMUNOGENIC PEPTIDES AND METHODS FOR PRODUCERS
BRPI0410953A (en) elastomeric deposit compositions which may be implanted, uses thereof and production process
PE20060244A1 (en) PHARMACEUTICAL DEPOSIT FORMULATION CONTAINING POLYETHYLENE GLYCOL OF MOLECULAR WEIGHT LESS THAN 600 DALTONS
AR045016A1 (en) DERIVATIVES OF 5-CARBAMIMIDOI-2-METILSULFANILTIOFEN-3-SULFONIL AS CONJUGATED INHIBITORS OF THE COMPLEMENT CASCADE AND ITS USE IN THE TREATMENT OF DISEASES.
UA110806C2 (en) MYCOBACTERIAL ANTIGENIC COMPOSITION
AR120079A1 (en) SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
PE20090711A1 (en) CONSTANT REGION OF MUTANT ANTIBODY
GEP20063860B (en) Chemically-modified human growth hormone conjugates
NO2016007I1 (en) Susoktokog
AR069903A1 (en) ANTIBODY CONJUGATE - ASSOCIATED MOLECULA DIRECTED TO THE PROTEIN TIROSINA QUINASA 7 (PTK 7), PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, NUCLEIC ACID, EXPRESSION FACTOR AND RELATED HUMAN CELL AND ITS USE TO PREPARE A MEDICATION
BR0207658A (en) Methods for treating or preventing disorders, diseases or conditions responsive to melanocortin-4 receptor activation, obesity, diabetes mellitus, male or female sexual dysfunction, and erectile dysfunction in a mammal in need thereof, and, pharmaceutical composition
DE60004172D1 (en) GCSF CONJUGATE
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
CY1106723T1 (en) N-TERMINAL MONOPEGYLATED CONJUGATES OF HUMAN GROWTH HORMONE, PROCESSES FOR THEIR PREPARATION AND METHODS OF USING THEREOF
MX338134B (en) Acid salt forms of polymer-drug conjugates and alkoxylation methods.
NO20070746L (en) Use of phosphated alkanols as dispersants, emulsifiers, hydrotropes, wetting agents and compatibility agents in agricultural compositions.
AR077611A1 (en) METHOD AND SET OF ELEMENTS (KIT) TO TREAT ADDICTION TO NICOTINE. COMBINATION. USE.
UA93254C2 (en) Process for producing insulin preparation for peroral use
PE20141549A1 (en) MATURE CRIG VARIANTS BY AFFINITY
CL2008002275A1 (en) Process to produce 3-chloro-n- (3-chloro-5-trifluoromethyl-2-pyridyl) -a, a, a-trifluoro-2,6-dinitro-p-toluidine using a solvent such as ketones, nitriles, esters and ethers in the presence of 20 to 40% w / w of water.
EA200800299A1 (en) WATER ANESTHESIC COMPOSITIONS CONTAINING PROPHOFOL
BRPI0519606A2 (en) synthesis, production and utility of taurine as a remedy
AR067085A1 (en) HOMOGENOUS VACCINE COMPOSITION FOR THE TREATMENT OF CANCER AND ITS METHOD OF OBTAINING
ATE462430T1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING INCONTINENCE

Legal Events

Date Code Title Description
FD Application declared void or lapsed